A Study of the Correlation Between the Debilitating State of the Elderly and Propofol Sensitivity (NCT06870357) | Clinical Trial Compass
CompletedEarly Phase 1
A Study of the Correlation Between the Debilitating State of the Elderly and Propofol Sensitivity
China128 participantsStarted 2024-01-20
Plain-language summary
In an aging society, there is a surge in the number of surgeries for elderly patients in hospitals, and the elderly are at greater risk of anesthesia due to their own characteristics: slowing metabolism, decreasing resistance, and decreasing physical function, and increased sensitivity to propofol. However, there are large individual differences, and anesthesiologists have found that they cannot judge a patient's sensitivity to anesthetic drugs based on age alone. Patients with different levels of debilitation have different sensitivities to propofol. The use of measuring telomere length to assess the debilitating state of the elderly is a novel and reliable assessment method. Then the sensitivity to propofol of people with different debilitating states was studied, so as to guide anesthesiologists to use drugs safely and reasonably, with a view to realizing the purpose of precise anesthesia.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 65 years
* American Society of Anesthesiologists (ASA) Classification I-IV
* No previous history of central nervous system disease, no history of psychiatric disorders, no contraindications to anesthesia
* No use of sedative drugs or opioids within 24h
* Approval and consent by the Ethics Committee of Shanxi Medical University and written informed consent by the patient (or authorized delegate)
Exclusion Criteria:
* leukemia patient
* Patients with hearing and visual impairments, communication disorders, inability to complete the debilitating state test
* Patient or family refused to participate in this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
telomere length
Timeframe: 24 hours
2
Loss of consciousness time
Timeframe: 24 hours
3
awakening time
Timeframe: 24 hours
4
Propofol dosage
Timeframe: 24 hours
5
Mean Arterial Pressure (MAP)
Timeframe: 24 hours
6
heart rate
Timeframe: 24 hours
7
Electroencephalographic dual frequency index (BIS value)
Timeframe: 24 hours
8
Incidence of adverse effects (hypotension, bradycardia, respiratory depression)
Timeframe: 24 hours
Trial details
NCT IDNCT06870357
SponsorSecond Hospital of Shanxi Medical University